Medicine
Volume 36, Issue 1 , Pages 24-28, January 2008

Cytotoxic chemotherapy: clinical aspects

Pippa G Corrie PhD FRCP is Consultant Medical Oncologist at Addenbrooke’s Hospital and the University of Cambridge, Cambridge, UK. She qualified from Oxford University and trained in medical oncology in Birmingham. Her specialist expertise is in the conduct of clinical trials, with particular emphasis on melanoma and hepatopancreaticobiliary malignancies. Competing interests: none declared

Abstract 

Cytotoxic chemotherapy drugs primarily damage proliferating cells and we now know the molecular target of most of the drugs in clinical use. Even so, non-specificity of cytotoxic agents is a major drawback and potential to damage normal tissues means that cure with chemotherapy is not often achieved. With advances in science, rational drug design is now becoming a reality, but these mechanism-driven, targeted agents are likely to be additions to, rather than substitutes for, conventional chemotherapy drugs. As cancer treatment becomes increasingly complex, the challenge for clinicians and scientists now is to manipulate our treatments to maximize benefit and minimize harm for the individual patient.

Keywords: application, cancer, cancer treatment, chemotherapy, cytotoxic agents

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1357-3039(07)00349-0

doi:10.1016/j.mpmed.2007.10.012

Medicine
Volume 36, Issue 1 , Pages 24-28, January 2008